J Pediatr Infect Dis 2019; 14(05): 253-259
DOI: 10.1055/s-0039-1694710
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Prophylactic Fucose can Alleviate Lipopolysaccharide-Induced Cholestatic Liver Injury in Neonatal Rats

Bora Baysal
1  Department of Neonatology, Dokuz Eylul University School of Medicine, Izmir, Turkey
,
Funda Tüzün
1  Department of Neonatology, Dokuz Eylul University School of Medicine, Izmir, Turkey
,
Defne Engür
2  Department of Neonatology, University of Medical Sciences, Tepecik Training Hospital, Izmir, Turkey
,
Seda Özbal
3  Department of Basic Medical Sciences, Dokuz Eylul University School of Medicine, Izmir, Turkey
,
BekirUğur Ergür
3  Department of Basic Medical Sciences, Dokuz Eylul University School of Medicine, Izmir, Turkey
,
Burçin İşcan
1  Department of Neonatology, Dokuz Eylul University School of Medicine, Izmir, Turkey
,
Ebru Yücesoy
1  Department of Neonatology, Dokuz Eylul University School of Medicine, Izmir, Turkey
,
Nuray Duman
1  Department of Neonatology, Dokuz Eylul University School of Medicine, Izmir, Turkey
,
Hasan Özkan
1  Department of Neonatology, Dokuz Eylul University School of Medicine, Izmir, Turkey
,
Abdullah Kumral
1  Department of Neonatology, Dokuz Eylul University School of Medicine, Izmir, Turkey
› Author Affiliations
Funding The study was financially supported by TUBITAK (Project Number: 115S953).
Further Information

Publication History

12 March 2019

25 June 2019

Publication Date:
13 August 2019 (eFirst)

Abstract

Objectives Cholestasis is a common disease of the liver in premature infants and no specific preventive treatment is currently available. Fucose, one of the monosaccharide building blocks of human milk oligosaccharides, may prevent cholestatic hepatic injury by various mechanisms. The aim of this study was to investigate the protective effect of fucose treatment after endotoxin-induced cholestasis in a rat model.

Methods Wistar rat pups were divided into four groups as: group I, control group; group II, fucose-supplemented group; group III, lipopolysaccharide (LPS)-administered group, and group IV, LPS-exposed and fucose-supplemented group. Fucose was given 100 mg/kg i.p. every other day between PN5–17. LPS was administered on PN19 to establish endotoxin-induced cholestasis model. On PN21, animals were sacrificed to evaluate liver cell damage and apoptosis.

Results Fucose supplementation significantly improved the biochemical parameters that deteriorated in LPS-administered group, significantly increased the expression of bile salt export pump, reduced the number of apoptotic cell death, and greatly prevented LPS-induced cholestatic hepatic injury.

Conclusion Given our results, fucose may be useful in reducing hepatic injury and might possess clinical relevance for the preventive treatment of inflammation-induced cholestatic injury in newborns.

Note

This study was conducted in the Neonatology Department of Dokuz Eylul University School of Medicine, Izmir, Turkey. Any affiliations with or involvement in any organization or entity with direct financial interest in the subject matter or materials discussed in the manuscript are disclosed in the paper.